Age: 60.0
Sex: F
Vaccine: COVID19, UNK, UNK
Symptoms: Condition aggravated, Dry skin, Injection site discomfort, Petechiae, Skin exfoliation
Clinical narrative: Puffiness, dry and scaly skin; Puffiness, dry and scaly skin; Puffiness, dry and scaly skin; Raw and chapped skin at every injection site; Patient also developed a pinpoint dot under her eye that bled; Swelling in all the areas; Symptoms have worsened; This is a spontaneous report received from contactable reporter(s) (Other HCP). Other Case identifier(s): GL-020322-2871 (Galderma).  A 60 year-old female patient received bnt162b2 (BNT162B2), administration date 11Nov2021 (Batch/Lot number: unknown) at the age of 60 years as dose 3 (booster), single for covid-19 immunisation; hyaluronic acid, lidocaine (RESTYLANE L), from 27Jul2021 (Lot number: 16885, Expiration Date: Dec2021) to 27Jul2021 at right nasolabial fold 0.3 ml, left nasolabial folds 0.3 ml, right jawline 0.35; hyaluronic acid, lidocaine hydrochloride (RESTYLANE DEFYNE), from 27Jul2021 (Lot number: 18562, Expiration Date: Aug2022) to 27Jul2021 at right cheek 0.25 ml, left cheek 0.25 ml. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for COVID-19 Immunization; Bnt162b2 (Dose: 2), for COVID-19 Immunization.  The following information was reported: PETECHIAE (non-serious), outcome "recovered", described as "Patient also developed a pinpoint dot under her eye that bled"; SWELLING (non-serious) with onset 29Jan2022, outcome "unknown", described as "Swelling in all the areas"; SKIN SWELLING (non-serious), DRY SKIN (non-serious), SKIN EXFOLIATION (non-serious), outcome "unknown" and all described as "Puffiness, dry and scaly skin"; INJECTION SITE DISCOMFORT (non-serious), outcome "unknown", described as "Raw and chapped skin at every injection site"; CONDITION AGGRAVATED (non-serious) with onset 29Jan2022, outcome "unknown", described as "Symptoms have worsened". Therapeutic measures were not taken as a result of petechiae, swelling, skin swelling, dry skin, skin exfoliation, injection site discomfort, condition aggravated.  Additional information included: Nurse reported that a patient received injections with Restylane L in the high cheeks, tear troughs, oral commissures, nasolabial folds, 1 mL total and also injections with Restylane Defyne in the jawline and chin, also 1 mL, all on 27Jul2021. Nurse reported the patient had no issues and then on 29Jan2022 the patient noticed swelling in all the areas where she had the fillers placed in Jul2021. Nurse reported the patient developed puffiness, dry and scaly skin (like fish scales), raw and chapped skin at every injection site. Nurse reported the patient also developed a pinpoint dot under her eye that bled but that had now resolved. Nurse reported the patient's symptoms had worsened since 29Jan2022 and had an appointment to come into the office tomorrow. No treatment was provided yet. Nurse reported no known medical history or allergies for the patient. Nurse reported the patient had been using Restylane products ever since 2019 with no issues. Nurse reported no known illnesses in the month prior to treatment and no dental procedures in the past 6-12 months prior to treatment. Nurse reported it was unknown if the patient received any vaccines other than the Covid 19 vaccine. Nurse reported the first and second doses of the Covid 19 vaccine were administered on an unknown date prior to treatment and were of Pfizer brand. The Pfizer Covid 19 booster was administered on 11Nov2021. On 02Jan2019 Restylane L (Lot number: 16376 x2, Expiry: May2021) was administered in tear trough, cheek lines, OCs, nasolabial creases and jawline. Tear troughs: Right 0.35 ml Left 0.2 ml, Cheekline: Right 0.25 ml, Left 0.2ml, OC Right 0.55 ml OC Left 0.3 ml, Nasolabial folds: Right 0.1 ml Left 0.1 ml, Jawline Right 0.1 ml Left 0.1 ml. On 14Mar2019 Restylane L (Lot number: 16544, Expiry: Sep2021) was administered in cheeks, and OCs, Right cheek 0.2 ml, Left Cheek 0.15 ml, Right OC 0.3 ml, Left OC 0.3 ml.  On 12Aug2019 Restylane L (Lot number: 16585, Expiry: Oct2021) was administered in Cheeks, OCs, and jawline. Right cheek 0.2 ml, Left cheek 0.25 ml, Right OC 0.3 ml, Left OC 0.1 ml, Right Jawline 0.5 ml, Left Jawline 0.5 ml.  On 10Mar2020 Restylane Lyft (Lot number: Unknown, Expiry: Jul2022) was administered in OC and jawline . Amount injected is unknown. On 28Oct2020 Restylane Lyft (Lot number: 17082, Expiration: Feb2022) was administered in OCs, jawline and nasolabial folds. Right OC 0.15 ml, Left OC 0.15 ml, Right nasolabial fold 0.1 ml, Left nasolabial fold 0.1 ml, Right jawline 0.25 ml, Left jawline 0.25 ml.  On 27Jul2021 Restylane L (Lot number: 16885, Expiry: Dec2021) was administered in Right nasolabial fold 0.3 ml, Left nasolabial folds 0.3 ml, Right jawline 0.35, Left jawline 0.3 ml. Restylane Defyne (Lot number:18562, Expiry: Aug2022) was administered in Right cheek 0.25 ml, Left cheek 0.25 ml, Right OC 0.35 ml, Left OC 0.15 ml.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.